Stephen F. Betz - Nov 27, 2023 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Signature
/s/ Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Nov 27, 2023
Transactions value $
-$95,520
Form type
4
Date filed
11/29/2023, 04:31 PM
Previous filing
Mar 17, 2023
Next filing
Dec 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Sale -$95.5K -3K -3.4% $31.84 85.3K Nov 27, 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan.
F2 The common stock was sold by the Reporting Person in open market transactions on the transaction date with a volume weighted average sales price of $31.84 per share. The range of sales prices on the transaction date was $31.41 to $31.94 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F3 Includes 1,419 shares acquired under the Issuer's Employee Stock Purchase.